Form D · Biotechnology
Intellia Therapeutics, Inc.
Cambridge, MA · CIK 0001652130
Offering snapshot reported Sep 3, 2015 · SEC filing
- Reported sold
- $70M Offering amount: $70M
- Investors reported
- 28 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 20, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 3, 2015 | Initial | $70,017,155 | No comparison | 28 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $2.34M
- Finders' fees
- $0
- Form D file number
- 021-247004
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Leerink Partners LLC | 39011 |
Source: Form D, filed Sep 3, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Nessan Bermingham | Director, Executive |
| Jean Francois Formela | Director |
| Carl Gordon | Director |
| Rachel Haurwitz | Director |
| John Leonard | Director, Executive |
| Jose Rivera | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
130 Brookline Street Suite 201
Cambridge, MA, 02139
Cambridge, MA, 02139